PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
41.00%
Gross profit growth of 41.00% while RVPH is zero. Bruce Berkowitz would see if minimal improvements could expand further.
27.93%
EBIT growth above 1.5x RVPH's 6.73%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
27.93%
Operating income growth above 1.5x RVPH's 6.73%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
29.77%
Net income growth above 1.5x RVPH's 7.31%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
30.61%
EPS growth under 50% of RVPH's 100.00%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
30.61%
Diluted EPS growth under 50% of RVPH's 100.00%. Michael Burry would worry about an eroding competitive position or excessive dilution.
2.13%
Slight or no buybacks while RVPH is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
2.13%
Slight or no buyback while RVPH is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
32.67%
Positive OCF growth while RVPH is negative. John Neff would see this as a clear operational advantage vs. the competitor.
32.86%
Positive FCF growth while RVPH is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
83.05%
Positive long-term OCF/share growth while RVPH is negative. John Neff would see a structural advantage in sustained cash generation.
75.83%
Positive OCF/share growth while RVPH is negative. John Neff might see a comparative advantage in operational cash viability.
20.41%
3Y OCF/share CAGR under 50% of RVPH's 100.00%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
95.17%
Positive 10Y CAGR while RVPH is negative. John Neff might see a substantial advantage in bottom-line trajectory.
79.59%
Positive 5Y CAGR while RVPH is negative. John Neff might view this as a strong mid-term relative advantage.
2.82%
Below 50% of RVPH's 100.00%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
170.99%
Equity/share CAGR of 170.99% while RVPH is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-42.91%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-60.55%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while RVPH invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.43%
Negative asset growth while RVPH invests at 339.95%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-18.27%
We have a declining book value while RVPH shows 100.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-4.43%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-31.86%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-15.50%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.